[go: up one dir, main page]

TW200716621A - Polymorph form II of tanaproget - Google Patents

Polymorph form II of tanaproget

Info

Publication number
TW200716621A
TW200716621A TW095114816A TW95114816A TW200716621A TW 200716621 A TW200716621 A TW 200716621A TW 095114816 A TW095114816 A TW 095114816A TW 95114816 A TW95114816 A TW 95114816A TW 200716621 A TW200716621 A TW 200716621A
Authority
TW
Taiwan
Prior art keywords
polymorph form
tanaproget
processes
benign
tanaproget polymorph
Prior art date
Application number
TW095114816A
Other languages
English (en)
Inventor
Marc Sadler Tesconi
Mannching Sherry Ku
Yan Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200716621A publication Critical patent/TW200716621A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
TW095114816A 2005-04-28 2006-04-26 Polymorph form II of tanaproget TW200716621A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67573705P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
TW200716621A true TW200716621A (en) 2007-05-01

Family

ID=36954854

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114816A TW200716621A (en) 2005-04-28 2006-04-26 Polymorph form II of tanaproget

Country Status (11)

Country Link
US (4) US7759341B2 (zh)
EP (1) EP1874763A2 (zh)
JP (2) JP2008539258A (zh)
CN (1) CN101166736B (zh)
AR (1) AR053596A1 (zh)
AU (1) AU2006241125B2 (zh)
BR (1) BRPI0610433A2 (zh)
CA (1) CA2603807A1 (zh)
MX (1) MX2007013469A (zh)
TW (1) TW200716621A (zh)
WO (1) WO2006116526A2 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
SI1877059T1 (sl) 2005-04-28 2010-07-30 Wyeth Llc Mikroniziran tanaproget in sestavki, ki ga vsebujejo
PL1896034T3 (pl) * 2005-04-28 2010-07-30 Wyeth Llc Mikronizowane kompozycje tanaprogetu i sposoby ich wytwarzania
US20060280800A1 (en) 2005-06-09 2006-12-14 Wyeth Tanaproget compositions containing ethinyl estradiol
BRPI0819571A2 (pt) 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
CA2879982C (en) * 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
EP3353176B1 (en) 2015-09-24 2022-01-19 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131856C (zh) * 1999-05-04 2003-12-24 美国家庭用品有限公司 作为黄体酮受体调节剂的环硫代氨基甲酸酯衍生物
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1665510A (zh) * 2002-06-25 2005-09-07 惠氏公司 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
CA2489847A1 (en) * 2002-06-25 2003-12-31 Wyeth Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
PE20060331A1 (es) 2004-04-27 2006-05-16 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
WO2006020712A1 (en) * 2004-08-13 2006-02-23 Wyeth Tanaproget derivatives, metabolites, and uses thereof
BRPI0610438A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição
PL1896034T3 (pl) 2005-04-28 2010-07-30 Wyeth Llc Mikronizowane kompozycje tanaprogetu i sposoby ich wytwarzania
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
SI1877059T1 (sl) 2005-04-28 2010-07-30 Wyeth Llc Mikroniziran tanaproget in sestavki, ki ga vsebujejo
CN101184738B (zh) 2005-04-28 2012-05-23 惠氏公司 纯化型的tanaproget
US20060280800A1 (en) 2005-06-09 2006-12-14 Wyeth Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
EP1874763A2 (en) 2008-01-09
AR053596A1 (es) 2007-05-09
JP2014088385A (ja) 2014-05-15
AU2006241125B2 (en) 2012-07-05
US8114869B2 (en) 2012-02-14
US20110212953A1 (en) 2011-09-01
MX2007013469A (es) 2008-01-22
BRPI0610433A2 (pt) 2010-11-23
CN101166736B (zh) 2013-02-06
WO2006116526A2 (en) 2006-11-02
CN101166736A (zh) 2008-04-23
AU2006241125A1 (en) 2006-11-02
US7968709B2 (en) 2011-06-28
WO2006116526A3 (en) 2007-06-28
US20100267715A1 (en) 2010-10-21
US20060247235A1 (en) 2006-11-02
US7759341B2 (en) 2010-07-20
WO2006116526A8 (en) 2007-08-16
US20120115858A1 (en) 2012-05-10
CA2603807A1 (en) 2006-11-02
JP2008539258A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
TW200716621A (en) Polymorph form II of tanaproget
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
EP1896034B8 (en) Micronized tanaproget compositions and methods of preparing the same
MX2007001608A (es) Modulares del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos.
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
JP2008539258A5 (zh)
WO2008021339A3 (en) Pyrrolidine and related derivatives useful as pr modulators
MX2009001698A (es) Derivados de oxazolidona como moduladores pr.
PL1874278T3 (pl) Kompozycje zawierające mikronizowany tanaproget
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
DE602005019905D1 (de) -modulatoren
WO2008109055A3 (en) Cyanopyrrole sulfonamides useful for modulation of the progesterone receptor
ATE275973T1 (de) Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten
CR9598A (es) Moduladores no esteroides de receptor de progesterona
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
WO2008112498A3 (en) Synthesis and characterization of polymorph form ii of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
MX2008000070A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona.